EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
Included in Issue 3 of European Pharmaceutical Review:
FOREWORD
Contaminated medicines: an issue that won’t go away
David Elder, David P Elder Consultancy
IN-DEPTH FOCUS: Downstream processing
Filter breakthrough evaluation for polysorbate 80 in protein formulations
Gregory Webster and Mirko Pauli, AbbVie
MANUFACTURING
Mastering sterile fill finish in the age of advanced therapies
Tommy Schornak, Kindeva
DRUG FORMULATION
European ruling clears titanium dioxide for continued use
Dominic Tyer, European Pharmaceutical Review
IN-DEPTH FOCUS: Drug development
Alliance for impact – advancing CGT development in Europe
Lindsay Davies, ISCT
IN-DEPTH FOCUS: Microbiology/RMM
Illuminating the invisible: advantages and disadvantages of ATP detection
Tim Sandle, Bio Products Laboratory
Leveraging automation in the microbiology lab
Karen Capper, AstraZeneca
Interested? Register now to access this exclusive content
Download Now
European Pharmaceutical Review Issue 3 2025
Topics
- AbbVie
- Advanced therapies manufacturing
- AI, analytics and decision support
- Analytical and bioanalysis
- AstraZeneca
- Automation and robotics
- Big Pharma
- Biologics formulation and stability
- Bioprocessing and biomanufacturing
- CDMO/CMO operations
- Clinical Development
- Clinical Trials
- Continuous manufacturing and PAT
- Data Analysis
- David Elder (David P Elder Consultancy)
- Excipients and raw materials
- Facilities, utilities and cleanrooms
- Formulation and drug delivery
- Gregory Webster (AbbVie)
- Industry Insight
- Kindeva Drug Delivery
- Lindsay Davies (ISCT)
- Mirko Pauli (AbbVie)
- Pharmacovigilance and safety oversight
- Production
- Quality, microbiology and contamination control
- Rapid Microbiological Methods (RMMs)
- Regulation and compliance
- Sterility and rapid methods
- Technology
- Therapeutics
- Tim Sandle (Bio Products Laboratory)
- Tommy Schornak (Kindeva)
- Upstream processing
